(Q35543586)

8 August 2017

1 reference

title

Natural history of hepatitis C and outcomes following liver transplantation. (English)

1 reference

8 August 2017

main subject

liver transplantation

1 reference

1 reference

Michael Charlton

1

1 reference

8 August 2017

publication date

1 August 2003

1 reference

8 August 2017

published in

Clinics in liver disease

1 reference

8 August 2017

volume

7

1 reference

8 August 2017

issue

3

1 reference

8 August 2017

page(s)

585-602

1 reference

Long-term outcome of hepatitis C virus infection after liver transplantation

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Recurrent and new hepatitis C virus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Long-term outcome of hepatitis C infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Liver transplantation in hepatitis C. A Spanish multi-centre experience

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

A longitudinal analysis of hepatitis C virus replication following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Hepatitis C virus kinetics during and immediately after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Causes of graft loss following liver transplantation for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Predictors of patient and graft survival following liver transplantation for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

The association between hepatitis C infection and survival after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Influence of the dynamics of the hypervariable region 1 of hepatitis C virus (HCV) on the histological severity of HCV recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Ribavirin therapy for hepatitis C infection following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Long-term ribavirin therapy for recurrent hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

The prevalence of hepatitis C virus (HCV) in infants and children after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

The pathogenesis of hepatitis C virus is influenced by cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Interferon-alpha therapy for hepatitis C virus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Immunological and virological effects of ribavirin in hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900046-1

7 January 2021

10.1016/S1089-3261(03)00046-1

Identifiers

DOI

1 reference

8 August 2017

1 reference